AK3280 clinical trials
Also written AK3280.
How each study uses AK3280 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AK3280 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AK3280
- 4
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Shanghai Ark Biopharmaceutical Co., Ltd. (4)
Studies
Open first, then newest update. How each study uses AK3280 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingPhase 3Shanghai Ark Biopharmaceutical Co., Ltd.NCT07719023Written as AK3280
- A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisStatus unknownPhase 2Shanghai Ark Biopharmaceutical Co., Ltd.NCT05424887Written as AK3280
- A Study of AK3280 in Chinese Healthy VolunteersCompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT04926116Written as AK3280
- A Study to Assess the Effect of AK3280 on Renal Function in Healthy SubjectsCompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT03990688Written as AK3280